CD8A and neoplasm: In conclusion, we have developed a novel tumor vaccine system GP‐Neoantigen based on yeast polysaccharide shell particles, which can stimulate the body to produce a strong antigen‐specific CD8+ T cell immune response against various neoantigen peptides and thus be used for effective tumor treatment.